Mangoceuticals, Stock Based Compensation To Revenue from 2010 to 2025
| MGRX Stock | 2.61 0.07 2.61% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 0.98 | Current Value 0.93 | Quarterly Volatility 10.1850935 |
Check Mangoceuticals, Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mangoceuticals, Common's main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.4 K, Interest Expense of 0.0 or Selling General Administrative of 7.8 M, as well as many indicators such as Price To Sales Ratio of 8.85, Dividend Yield of 0.0 or PTB Ratio of 7.23. Mangoceuticals, financial statements analysis is a perfect complement when working with Mangoceuticals, Common Valuation or Volatility modules.
Mangoceuticals, | Stock Based Compensation To Revenue |
Latest Mangoceuticals, Common's Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of Mangoceuticals, Common Stock over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. Mangoceuticals, Common's Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mangoceuticals, Common's overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
Mangoceuticals, Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 21.45 | |
| Geometric Mean | 13.98 | |
| Coefficient Of Variation | 47.48 | |
| Mean Deviation | 7.70 | |
| Median | 26.19 | |
| Standard Deviation | 10.19 | |
| Sample Variance | 103.74 | |
| Range | 25.3336 | |
| R-Value | (0.68) | |
| Mean Square Error | 60.17 | |
| R-Squared | 0.46 | |
| Significance | 0 | |
| Slope | (1.45) | |
| Total Sum of Squares | 1,556 |
Mangoceuticals, Stock Based Compensation To Revenue History
About Mangoceuticals, Common Financial Statements
Mangoceuticals, Common investors use historical fundamental indicators, such as Mangoceuticals, Common's Stock Based Compensation To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Mangoceuticals, Common. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 0.98 | 0.93 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Additional Tools for Mangoceuticals, Stock Analysis
When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.